ProtecT Study Publications Summary

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified
  Journal of Clinical Epidemiology
  2009, 62: 67-73

Development of a complex intervention improved randomisation and informed consent in a randomised controlled trial
  Journal of Clinical Epidemiology
  2009, 62: 29-36

Life course sun exposure and risk of prostate cancer: population-based nested case-control study (ProtecT)
  International Journal of Cancer
  2009
  Rebecca Gilbert; Chris Metcalfe; Steven Oliver; David Whiteman; Chris Bain; Andy Ness; Jenny Donovan; Freddie Hamdy; David Neal; J Athene Lane; Richard Martin

Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review & meta-analysis
  International Journal of Cancer
  2009
  Rowlands, M-A.

Development of a new model for PSA reference ranges for monitoring men with localised prostate cancer
  European Urology
  2009
  Tilling, K.

Low risk research using routine collected identifiable health information without informed consent.
  Medical Ethics
  2008, 34: 37-40
  Metcalfe, C.; Martin, R.M.; Noble, S.; Lane, J.A.; Donovan, J.

Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial
  European Urology
  2008, 53: 1186-1193
  Avery, K.N.L.; Blazeby, J.M.; Lane, J.A.; Neal, D.E.; Hamdy, F.C.; Donovan, J.L.
Multiple newly identified loci associated with prostate cancer susceptibility
Nature Genetics
2008, 40: 316-321
Eeles, RA; Kote-Jarail, Z; Giles, GG; Al Olama, AA; Guy, M; Jugurnauth, SK; Mulholland, S; Daniel, A; Leogamornlert, DA; Edwards, SM; Morrison, J; Field, HI; Southey, MC; Severi, G; Donovan, JL; Hamdy, FC

British Journal of Urology International
2008, 101: 547-555

Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Journal of the National Cancer Institute
2008, 100: 170-183
Roddam, A.W. et al

Prostate cancer mortality in the USA and UK 1975 - 2004: an ecological study
Lancet Oncology
2008, 9: 445-452

Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis
Cancer Epidemiology, Biomarkers & Prevention
2008, 17: 2325-2336
Zuccolo, L; Harris, R; Gunnell, D; Oliver, S; Lane, J.A; Davis, M; Donovan, J; Neal, D; Hamdy, F; Beynon, R; Savovic, J; Martin, R.M

Insulin-like Growth Factors, their Binding Proteins and Prostate Cancer Risk: A Collaborative Analysis of Individual Data from Twelve Prospective Studies
Annals Internal Medicine
2008, 149: 461-471
Roddam, A.W.; Allen, N.E.; Appleby, P.; Key, T.J.

Multiple Loci with Different Cancer Specifities Within the 8q24 Gene Desert
Journal of the National Cancer Institute
2008, 100: 962-966
The decision-related psychosocial concerns of men with localised prostate cancer: targets for intervention and research
World Journal of Urology
2008, 26: 469-474
Steginga, S.K.; Turner, E.; Donovan, J.

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
British Journal of Urology International
2008, 102: 1629-1633
Kerry N.L. Avery; Chris Metcalfe; Jane M. Blazeby; J. Athene Lane; David E. Neal; Freddie C. Hamdy; Jenny L. Donovan

Contribution of a single repeat PSA test to prostate cancer risk assessment - experience from the ProtecT Study.
European Urology
2007, 53: 777-784

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
British Medical Journal
2007, 335: 1139-1143

Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men
The Prostate
2007, 67: 1816-1824
Bosch, J.L.H.R.; Tilling, K.; Bohnen, A.M.; Bangma, C.; Donovan, J.

How ProtecT aims to improve treatment for men with prostate cancer
Oncology Times
2007, 4: 6

Screening for prostate cancer.
(Book chapter)
2006, 3: 102-110
Hamdy, F.C.; Donovan, J.L.; Neal, D.E.
Establishing Normal Reference Ranges for PSA Change With Age in a Population-Based Study: The Krimpen-Study
The Prostate
2006, 66: 335-343
Bosch, J.L.H.R.; Tilling, K.; Bohnen, A.M.; Donovan, J.L.

Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the Prostate Specific Antigen Era.
Journal of Urology
2006, 176: 439-449
Martin, R.M.; Gunnell, D.; Hamdy, F.; Neal, D.; Lane, J.A.; Donovan, J.L.

Screening for prostate cancer.
Trends in Urology Gynaecology and Sexual Health
2006, 11: 20-25
Martin, R.M.; Donovan, J.L.; Verne, J.

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT) study.
Contemporary Clinical Trials
2006, 27: 413-419
Mills, N.; Chris Metcalfe; Carine Ronsmans; Michael Davis; J. Athene Lane; Jonathan A.C. Sterne; Tim J. Peters; Freddie C. Hamdy; David E. Neal; Jenny L. Donovan

A model of the natural history of screen-detected prostate cancer.
British Journal of Cancer
2006, 95: 1122-1123
Metcalfe, C.; Lane, J.A.; Hamdy, F.; Neal, D.; Donovan, J.L.

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
British Journal of Urology International
2006, 98: 777-782

Statins and risk of cancer: A systematic review and meta-analysis
International Journal of Cancer
2006, 120: 833-843
Browning, D.R.L.; Martin, R.M.

Screening for prostate cancer - the case against.
Annals of the Royal College of Surgeons
2005, 87: 90-91
Donovan, J.L.; Hamdy, F.C.; Neal, D.E.
Screening for prostate cancer - from the Year in Urology.
The Year in Urology
2005, 2: 152-166
Donovan, J.L.

Reviewing negative prostatic core biopsies for the multidisciplinary team meeting.
Histopathology
2005, 47: 643-644
Oxley, J.

Does current evidence justify prostate cancer screening in Europe?
Nature Clinical Practice Oncology Review
2005, 2: 538-539
Martin, R.M.; Davey Smith, G.; Donovan, J.L.

Prostate cancer: Screening approaches.
British Journal of Hospital Medicine
2005, 66: 623-626

Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer.
Cancer Epidemiology Biomarkers and Prevention
2004, 13: 163-165

Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study.
International Journal of Cancer
2004, 108: 887-892

Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?
Journal of Clinical Endocrinology and Metabolism
2004, 89: 213-218

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Urology
2004, 64: 317-322
Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study
Controlled Clinical Trials  
2003, 24: 272-282
Mills, N.; Jenny Donovan; Monica Smith; Ann Jacoby; David Neal; Freddie Hamdy

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study)  
Journal of Clinical Epidemiology  
2003, 56: 605-609
Donovan, J.L.; Tim Peters; Sian Noble; Philip Powell; David Gillatt; Steven Oliver; Athene Lane; David Neal; Freddie Hamdy

Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion.  
British Journal of Urology International  
2003, 91: 331-336
Oliver, S.E.; Donovan, J.L.; Peters, T.J.; Frankel, S.; Hamdy, F.C.; Neal, D.E.

British Journal of Cancer  
2003, 88: 1682-1686

Ethics of clinical trials from bayesian perspective: Randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer.  
British Medical Journal  
2003, 326: 1456-1456
Hamdy, F.C.; Donovan, J.L.; Lane, J.A.; Neal, D.E.

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.  
Health Technology Assessment  
2003, 7

Screening for prostate cancer.  
The Lancet  
2003, 361: 1122-1128
Frankel, S.; Davey-Smith, G.; Donovan, J.; Neal, D.
Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT study.
    British Medical Journal
    2002, 325: 766-770

Clinical oncologists favour radical radiotherapy for localised prostate cancer: a questionnaire survey.
    British Journal of Urology International
    2002, 90: 558-560
    Hanna, C.L.; Mason, M.D.; Donovan, J.L.; Barber, J.P.

    European Journal of Public Health
    2000, 10: 289-295

Comparison of trends in prostate-cancer mortality in England, Wales and the USA.
    The Lancet
    2000, 355: 1788-1789
    Oliver, S.E.; Gunnell, D.; Donovan, J.L.

Unanswered questions in screening for prostate cancer.
    European Journal of Cancer
    2000, 36: 1316-1321

Prostate cancer: to screen or not to screen?
    The Lancet Oncology
    2000, 1: 17-24
    Neal, D.E.; Donovan, J.L.

Screening for prostate cancer in the UK: Seems to be creeping in by the back door.
    British Medical Journal
    2000, 323: 763-764
    Donovan, J.L.; Frankel, S.J.; Neal, D.E.; Hamdy, F.C.

Capturing user's experiences of participating in cancer trials.
    European Journal of Cancer
    2000, 11: 210-214
    Donovan, J.L.; Brindle, L.; Mills, N.


Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom.
    British Medical Journal
    1999, 318: 299-300

Screening for prostate cancer.
    Annals of Oncology
    1998, 9: 1289-1292
    Neal, D.E.

Diagnosis, management and screening of early localised prostate cancer: a review
    Health Technology Assessment
    1997, 1: 1-95
    Selley, S.; Donovan, J.L.; Faulkner, A.; Coast, J.; Gillatt, D.

Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research
    Journal of Health Services Research & Policy
    Noble, S